Medical therapy for pulmonary arterial hypertension (Q37030844)

17 August 2017

1 reference

title

Medical therapy for pulmonary arterial hypertension (English)

1 reference

17 August 2017

main subject

arterial hypertension

0 references

author name string

James A Driscoll

series ordinal

1

1 reference

17 August 2017

Murali M Chakinala

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

9

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

65-81

1 reference

Clinical classification of pulmonary hypertension.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Cellular and molecular pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Pathobiology of pulmonary hypertension. The role of platelets and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Increased plasma serotonin in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Hemodynamics and survival of patients with portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Medical therapy of pulmonary hypertension. Conventional therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Prostanoid therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Endothelin receptor antagonists in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Treatment of primary pulmonary hypertension -- the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Cardiovascular effects of phosphodiesterase 5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Tadalafil in primary pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Long term imatinib treatment in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Rho-kinase is an important therapeutic target in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Attenuation of chronic hypoxic pulmonary hypertension by simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Tricuspid annular displacement predicts survival in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.65

21 January 2018

Identifiers

DOI

10.1517/14656566.9.1.65

1 reference

17 August 2017

1 reference